PMC:7091888 / 960-1362 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"33","span":{"begin":116,"end":120},"obj":"Gene"},{"id":"44","span":{"begin":14,"end":22},"obj":"Species"},{"id":"45","span":{"begin":81,"end":91},"obj":"Species"},{"id":"46","span":{"begin":100,"end":108},"obj":"Species"},{"id":"47","span":{"begin":186,"end":194},"obj":"Species"},{"id":"48","span":{"begin":242,"end":252},"obj":"Species"},{"id":"49","span":{"begin":270,"end":278},"obj":"Species"},{"id":"50","span":{"begin":323,"end":333},"obj":"Species"},{"id":"51","span":{"begin":371,"end":379},"obj":"Species"},{"id":"56","span":{"begin":161,"end":170},"obj":"Disease"}],"attributes":[{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"Gene:59272"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"Tax:694009"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"Tax:2697049"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:694009"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Tax:694009"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:2697049"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:694009"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:2697049"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:694009"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":132,"end":137},"obj":"Body_part"},{"id":"T6","span":{"begin":179,"end":184},"obj":"Body_part"},{"id":"T7","span":{"begin":257,"end":264},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T12","span":{"begin":14,"end":22},"obj":"Disease"},{"id":"T13","span":{"begin":14,"end":18},"obj":"Disease"},{"id":"T14","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"T15","span":{"begin":81,"end":85},"obj":"Disease"},{"id":"T16","span":{"begin":100,"end":108},"obj":"Disease"},{"id":"T17","span":{"begin":100,"end":104},"obj":"Disease"},{"id":"T18","span":{"begin":161,"end":170},"obj":"Disease"},{"id":"T19","span":{"begin":186,"end":194},"obj":"Disease"},{"id":"T20","span":{"begin":186,"end":190},"obj":"Disease"},{"id":"T21","span":{"begin":242,"end":250},"obj":"Disease"},{"id":"T22","span":{"begin":242,"end":246},"obj":"Disease"},{"id":"T23","span":{"begin":270,"end":278},"obj":"Disease"},{"id":"T24","span":{"begin":270,"end":274},"obj":"Disease"},{"id":"T25","span":{"begin":323,"end":331},"obj":"Disease"},{"id":"T26","span":{"begin":323,"end":327},"obj":"Disease"},{"id":"T27","span":{"begin":371,"end":379},"obj":"Disease"},{"id":"T28","span":{"begin":371,"end":375},"obj":"Disease"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":132,"end":137},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T8","span":{"begin":179,"end":184},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T8","span":{"begin":257,"end":264},"obj":"Chemical"}],"attributes":[{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for"}